Karyopharm Therapeutics (NASDAQ:KPTI) Raised to Buy at StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report released on Thursday.

Several other research firms have also commented on KPTI. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Piper Sandler raised their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, November 1st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Karyopharm Therapeutics currently has an average rating of “Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 2.8 %

KPTI opened at $0.81 on Thursday. The stock has a market capitalization of $102.01 million, a P/E ratio of -0.71 and a beta of 0.16. The stock has a 50-day moving average price of $0.82 and a 200-day moving average price of $0.90. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to analysts’ expectations of $37.86 million. During the same period in the prior year, the company earned ($0.30) EPS. On average, equities research analysts predict that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP grew its stake in shares of Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after purchasing an additional 792,283 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after buying an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $494,000. Ikarian Capital LLC raised its holdings in shares of Karyopharm Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after acquiring an additional 9,355 shares in the last quarter. Finally, FMR LLC lifted its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after acquiring an additional 76,510 shares during the period. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).